Going Long on my position even with the drop... Few know this about $NVO Hidden in a Danish forest, Novo Nordisk runs the world’s largest insulin factory — producing 50% of world’s insulin.
When I traded in 2008 penny stocks OTCBB and OTC. I now know trade NASDAQ or other big board exchanges that are near cheap and look up quarterly net incomes and revenue. My most important indicator is Accumulation Distribution when playing dollar or penny stocks. Just look at $DLTH BEST LOOKING CHART I EVER SEEN LOW TARGET $7 WILL HOLD LONG TERM. ALL BUYING VOLUME ON FIRST EVER POSTIVE NET INCOME QUARTERLY. COMPANY IS ALL OVER USA HQ NEAR ME MOUNT HOREB WI. THIS A MILLION TIMES BUY ALL OVER CANT FIND WEAKNESS. STILL IN $CHR AT .17 TARGET 1.50.
In $LYB 48.82 at 25 shares. I got $34 quarterly dividend and only have 25 shares $LYB rocks! Update Dec 11th 2025 LyondellBasell Industries N.V. trades at an extreme valuation discount, with a 12.8% forward yield and 11.8x FY2 P/E. Recent Q3 earnings reflect cyclical and external headwinds, but consensus projects a robust EPS recovery starting FY 2026. LYB’s maintained dividend signals management’s confidence in navigating downturns and underscores the temporary nature of current challenges. Such a deep valuation discount positions LYB for outsized returns even with modest EPS recovery. Fair Value $LYB There is no consensus on the fair value of LyondellBasell Industries (LYB), with different analysis firms providing a wide range of estimates. Some models suggest the stock is undervalued, with fair values around $65.59 to $100 per share, while others indicate it may be overvalued based on price-to-earnings ratios. A key factor influencing these varied valuations is the company's inconsistent profitability and reliance on commodity chemical markets. Different fair value estimates $65.59: GuruFocus's GF Value is based on the company's historical trading multiples and growth prospects. $90.28: A Simply Wall Street analysis based on a 2-stage free cash flow to equity model suggests the stock is undervalued. $100: Morningstar's fair value estimate is $100 per share, based on their analysis of the company's profit decline and projected growth. $115: An updated view from Seeking Alpha using the current dividend and other factors estimates the fair value at $115 per share. Last Year Gain to Loss Ratio all in $LYB
